Total number of shares and voting rights in Zealand Pharma at December 30, 2021
Zealand Pharma (NASDAQ: ZEAL) reported its total number of shares and voting rights as of December 30, 2021, following the recent exercise of employee warrants. The company now has a total of 43,643,142 shares and 43,643,142 voting rights, reflecting its current share capital. This announcement complies with the Danish Capital Markets Act requirements. Zealand Pharma, focused on peptide-based medicines, has progressed more than 10 drug candidates into clinical development.
- Total shares increased to 43,643,142, indicating employee interest and possible growth.
- Two drug candidates have reached the market, with three in late-stage development.
- None.
Company announcement – No. 78 / 2021
Total number of shares and voting rights in Zealand Pharma at December 30, 2021
Copenhagen, DK and Boston, MA, December 30, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.
In Company announcement No. 74/2021 from December 10, 2021, Zealand announced an increase in share capital relating to the exercise of employee warrants. Following this announcement, the table below lists the total number of shares and voting rights in Zealand up to and including December 30, 2021.
Date | Number of shares (nominal value of DKK 1 each) | Share capital (nominal value in DKK) | Number of voting rights |
| December 30, 2021 | 43,643,142 | 43,643,142 | 43,643,142 |
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.
Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.
Forward-Looking Statement
The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.
For further information, please contact:
| Zealand Pharma Investor Relations |
| Maeve Conneighton |
| Argot Partners |
| investors@zealandpharma.com |
| Zealand Pharma Media Relations |
| David Rosen |
| Argot Partners |
| media@zealandpharma.com |
FAQ
What is the total number of shares for Zealand Pharma as of December 30, 2021?
How many voting rights does Zealand Pharma have?
What recent events affected Zealand Pharma's share capital?
When was Zealand Pharma's share capital last reported?
